|View printer-friendly version|
MiMedx Announces Receipt of Nasdaq Letter
The Nasdaq staff's letter states that the hearing would be expected to occur 30-45 days from the date of the hearing request. If the
The Company expects that it will provide an update once the
As previously disclosed, the Company's Audit Committee is conducting an independent internal investigation into current and prior-period matters concerning sales and distribution practices and other matters. The Company has also stated that it cannot file any restatements of its previously filed financial statements and related reports with the
While the MiMedx Audit Committee and its advisors are continuing to work diligently to complete its independent investigation to bring its
The Company is making this announcement in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a staff determination letter.
MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind the Company's mission to give physicians products and tissues to help the body heal itself. The Company processes the human placental tissue utilizing its proprietary PURION® Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization.
Robert P. Borchert, Vice President, Investor Relations, 770-651-9383, firstname.lastname@example.org